Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Potassium voltage-gated channel subfamily Q member 7 (Kv7 or KCNQ) channels are a family of voltage-gated potassium channels crucial for controlling membrane excitability in neurons, cardiac muscle, and other tissues. These channels mediate inhibitory potassium currents, stabilizing resting membrane potential and repolarizing cells after action potentials. Dysfunction or genetic mutations can lead to diseases characterized by increased cellular excitability, such as epilepsy, cardiac arrhythmias (Long QT syndrome), and deafness. Small-molecule activators are being developed as therapeutic agents to enhance channel opening and restore normal function.
KCNQ channel activators enhance channel opening, increasing potassium ion efflux and reducing membrane excitability.
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Potassium voltage-gated channel subfamily Q member 7 (Kv7).